Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luscid: SBRT + Pembrolizumab +/- IT Avelumab/Ipilimumab + myDC in Solid Tumors
NCT04571632Phase 2Unknown
- Sponsor
- UZ Brussel
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CD1c+ and CD141+ myeloid dendritic cell vaccine in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by UZ Brussel. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
CD1c+ and CD141+ myeloid dendritic cell vaccine
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04571632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571632.